In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

A Case of Unclear Septal Hypertrophy

The Clinical Case of the Month: December 2008

Case Presentation

A 48 year old man presented with a bifascicular block at a routine check-up. He did not complain for exertional dyspnoe or angina nor for syncopes or dizziness. Cardiac risk factors were not known, especially he had no arterial hypertension. There was no abnormality in the clinical examination. CK was elevated with 263 U/l (normal <171), Troponin I with 0,36 μg/l (<0,05). The echocardiogram revealed a dilated left ventricle (58 mm, Henry-index 120%) with a normal ejection fraction. He had a considerable left ventricular hypertrophy (diastolic septal wall thickness max. 19 mm). In an exercise test he could perform 150 W, the ECG showed several couplets.

Myocardial Disease

What further examinations would you recommend ?

A coronary angiography in a hospital near home was performed which was normal. The electrophysiological investigation showed a prolonged HV interval, therefore a DDD pacemaker was implanted. The patient then was referred to endomyocardial biopsy, which showed the following result:

Case of the month: ESC Working Group on Myocardial & Pericardial Diseases

Fig. 1:

Section of the endomyocardial biopsy of this patient, stained with an antibody specific for EN4, an endothelial antigen (blue), and hematoxilin for counterstaining of
Please note the brightened areas within the cardiomyocytes.

What do you think is the diagnosis in this patient, which further investigations should be performed?


The diagnosis of a Fabry disease, which was suspected after immunohistochemical investigation of the biopsy was confirmed by the enzyme test with an alpha-galactosidase activity reduced to 0,05 mmol/min/mg (normal 0,4-1,0). Genetic testing confirmed a transition C644A>G (N215S). Renal function as well as the findings of the opthalmologist and neurologist was normal. A family pedigree was drawn, no abnormalities were reported.

What would be the next steps concerning the patient and his family?

The diagnosis of Fabry disease was explained to the patient, and an enzyme replacement therapy was offered. This has started in the meantime and is well tolerated by the patient.
We offered enzyme testing and consulting to the family. Several family members were newly diagnosed as carriers of the same mutation (fig.2).

Case of the month: ESC Working Group on Myocardial & Pericardial Diseases

In otherwise unexplained cases cardiac hypertrophy might be the result of a storage disease. A careful clinical examination and history taking might give hints for a special form of disease, otherwise an endomyocardial biopsy can show typical alterations.

Fabry disease is a rare lysosomal storage disease caused by a deficiency of -galactosidase A, which results in progressive accumulation of globotriaosylceramid in different organs, leading e.g. to renal failure, neurovascular symptoms and neuropathic pain, gastrointestinal complaints, angiokeratomas and corneal dystrophy. Cardiac involvement commonly includes cardiomyopathy and rhythm disturbances
(e.g. bradyarrhythmia, AV-block, bundle branch block, ventricular tachycardias), rarely arterial disease and valvular disorders. Heart disease in Morbus Fabry might be the fatal complication.

Some years ago enzyme replacement therapy (ERT) was approved for the treatment of the disease. Several small clinical trials and observational studies show positive effects e.g. on renal function and cardiac mass whereas great randomised end-point studies are still on the way. In the meantime we have to carefully follow both patients and their asymptomatic relatives to find the optimal time to start ERT.


  1. Linhart A, Elliott P: The heart in Anderson-Fabry disease and other lysosomal staroage disorders. Heart 2007;93:528–535
  2. Linhart A, Kampman C, Zamorano JL et al.: Cardiac manifestations of Anderson–Fabry disease: results from the international Fabry outcome survey. Eur Heart Journal 2007; 28: 1228–1235
  3. Linhart A: Treatment of Anderson–Fabry disease. Heart 2008;94:138–139.
  4. Monserrat L, Gimeno-Blanes JR, Marı F et al.: Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2007;50:2399–403
  5. Zarate YA, Hopkin RJ: Fabry’s disease. Lancet 2008; 372: 1427–35

Notes to editor

Dr. Anette Richter & Dr. Sabine Pankuweit, University Hospital Marburg, Germany
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.